外科理论与实践2013，Vol.18Issue(1)：67-72,6.DOI:10.3969/j.issn.1007-9610.2013.01.017
血管内皮细胞生长因子受体在甲状腺髓样癌中的高表达
High expression of VEGFR-1 and VEGFR-2 in medullary thyroid carcinoma
康永利 1陈曦 2姜敏 2周光文1
作者信息
- 1. 上海交通大学医学院附属第一人民医院普外科,上海201600
- 2. 上海交通大学医学院附属瑞金医院外科,上海200025
- 折叠
摘要
Abstract
Objective To analyze the expression of VEGFR-1 and VEGFR-2 in samples for patients with medullary thyroid carcinoma (MTC) and to explore their correlation with clinical parameters. Methods Parafin-embedded samples from 24 patients with MTC (aged 44.9 ±14.1 years) were evaluated for VEGFR-1 and VEGFR-2 expression by immunohistochemistry. Clinical data were retrospectively reviewed. Results Eight patients (33.3%) had hereditary MTC. Six of them had multiple endocrine neoplasia (MEN)-2A and two MEN-2B. VEGFR-1 expression was detected in 91.7% (22/24) of MTC samples, VEGFR-2 in 87.5%(21/24). Age had positive correlation with VEGFR-2 (r=0.609, P=0.002). There was no correlation between VEGFR-2 and tumor stage (tumor node metastasis), tumor size, the relative decrease in serum CEA, or calcitonin before surgery and after. Nevertheless, VEGFR-1 was found to be inversely correlated with tumor node metastasis (r=-0.660, P=0.0005), and positively with the relative decrease in serum CEA and calcitonin before surgery and after (CEA: r=0.869; calcitonin:r=0.849, P<0.0001). We also observed a positive correlation between VEGFR-1 signal intensity and cure of disease (r=0.523, P=0.009). VEGFR-2 had no correlation with disease outcome through a follow-up period of 5.0±2.8 years (P=0.407). No difference were found for the staining intensity of VEGFR-1 and VEGFR-2 between hereditary and sporadic MTC (P>0.05). Conclusions The VEGFR-1 and VEGFR-2 overexpress in MTC patients and may be implicated in tumor progression.
关键词
甲状腺髓样癌/血管内皮细胞生长因子受体-1/血管内皮细胞生长因子受体-2/免疫组化Key words
Medullary thyroid carcinoma/ VEGFR-1/ VEGFR-2/ Immunohistochemistry分类
医药卫生引用本文复制引用
康永利,陈曦,姜敏,周光文..血管内皮细胞生长因子受体在甲状腺髓样癌中的高表达[J].外科理论与实践,2013,18(1):67-72,6.
